{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peng TR"],"funding":["Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation"],"pagination":["3676"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11545475"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(21)"],"pubmed_abstract":["<b>Background</b>: The KRAS G12C mutation, prevalent in various malignancies, including non-small cell lung cancer (NSCLC), represents a unique therapeutic target. Adagrasib and sotorasib, two FDA-approved agents specifically targeting this mutation, have shown promise in clinical trials. This study aims to compare their efficacy in treating KRAS G12C-mutated NSCLC, drawing insights from pivotal clinical trials. <b>Methods</b>: We analyzed data from three key clinical trials: KRYSTAL-1, CodeBreak100, and CodeBreak200. Our methodology involved reconstructing individual patient data from published Kaplan-Meier curves using the IPDfromKM tool (Version 0.1.10). The primary endpoints were progression-free survival (PFS) and overall survival (OS), evaluated through hazard ratios (HRs) and the re"],"journal":["Cancers"],"pubmed_title":["Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials."],"pmcid":["PMC11545475"],"funding_grant_id":["TCRD-TPE-113-50","TCRD-TPE-113-54"],"pubmed_authors":["Yi TY","Wu AJ","Peng TR","Wu TW"],"additional_accession":[]},"is_claimable":false,"name":"Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials.","description":"<b>Background</b>: The KRAS G12C mutation, prevalent in various malignancies, including non-small cell lung cancer (NSCLC), represents a unique therapeutic target. Adagrasib and sotorasib, two FDA-approved agents specifically targeting this mutation, have shown promise in clinical trials. This study aims to compare their efficacy in treating KRAS G12C-mutated NSCLC, drawing insights from pivotal clinical trials. <b>Methods</b>: We analyzed data from three key clinical trials: KRYSTAL-1, CodeBreak100, and CodeBreak200. Our methodology involved reconstructing individual patient data from published Kaplan-Meier curves using the IPDfromKM tool (Version 0.1.10). The primary endpoints were progression-free survival (PFS) and overall survival (OS), evaluated through hazard ratios (HRs) and the re","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-04-08T19:44:59.602Z","creation":"2025-04-19T17:29:05.305Z"},"accession":"S-EPMC11545475","cross_references":{"pubmed":["39518114"],"doi":["10.3390/cancers16213676"]}}